Macquarie Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Macquarie Group’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,338	Closed	-$6	–	2190
2024 Q1	$6	Buy	+1,338	New	+$4.66K	﹤0.01%	1777
2022 Q2	–	Sell	-842	Closed	-$6	–	2640
2022 Q1	$6	Hold	842	–	–	﹤0.01%	2587
2021 Q4	$9K	Hold	842	–	–	﹤0.01%	2526
2021 Q3	$11K	Hold	842	–	–	﹤0.01%	2536
2021 Q2	$18K	Hold	842	–	–	﹤0.01%	2384
2021 Q1	$20K	Sell	842 -258	-23%	-$6K	﹤0.01%	2290
2020 Q4	$20K	Hold	1,100	–	–	﹤0.01%	2225
2020 Q3	$13K	Hold	1,100	–	–	﹤0.01%	2251
2020 Q2	$27K	Buy	+1,100	New	+$18.2K	﹤0.01%	2095
2018 Q1	–	Sell	-600	Closed	-$12K	–	2405
2017 Q4	$12K	Buy	+600	New	+$12.9K	﹤0.01%	2244

Other funds holding GTHX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Macquarie Group's GTHX Position: Q2 2024 in Review

Macquarie Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 1,338 shares — an estimated $6 sold.

Macquarie Group first reported a position in GTHX in Q4 2017 and held it in 10 quarters. The position peaked at $27K in Q2 2020. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

Macquarie Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,338 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $6.
Macquarie Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 10 quarters.
Macquarie Group's G1 Therapeutics, Inc. Common Stock position peaked at $27K in Q2 2020.
88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.